<h4>Background</h4>PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). Here, CD274 is linked to classic Hodgkin lymphoma.